MedTrace Logo

Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC

NCT05203276 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-06-22

No results posted yet for this study

Summary

To evaluate the efficacy and safety of envafolimab combined with endostar in the first-line treatment of advanced Non-small Cell Lung Cancer With PD-L1 positive expression

Conditions

  • Lung Neoplasms

Interventions

DRUG

Envafolimab

300mg，SC，Q3W，d1

DRUG

Endostar

210mg，CIV，Q3W，d1-3

Sponsors & Collaborators

  • The First People's Hospital of Lianyungang

    lead OTHER

Principal Investigators

  • Xiaodong Jiang, Doc · The First People's Hospital of Lianyungang

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2024-05-30
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05203276 on ClinicalTrials.gov